EndoTODAY | EndoATLAS | Outpatient Clinic
Parasite | Esophagus | Stomach | Cancer | ESD
Home | Guide | Author | Subscription | Links
[»óºÎÀ§Àå°üÇ︮ÄÚ¹ÚÅÍÇÐȸ ¹× ÇÑÀÏÇ︮ÄÚ¹ÚÅÍ ÇÐȸ]
ÀϽÃ: 2017³â 4¿ù 7ÀÏ - 8ÀÏ
Àå¼Ò: Conrad Hotel, Seoul
1. [Meet the professor - breakfast session] Helicobacter negastive gastric cancer (Prof. Sugano, Jichi University)
ÇÐȸ ¶§¸¶´Ù breakfast sessionÀº ²À Âü¼®ÇÏ´Â ÆíÀÔ´Ï´Ù. ±×·±µ¥ À̹ø ÇÐȸ¸¸Å breakfast sessionÀÌ ´ë¼ºÈ²À» ÀÌ·é °ÍÀº º» ÀûÀÌ ¾ø½À´Ï´Ù. ´ë´ÜÇÑ ½Ã°£À̾ú½À´Ï´Ù.
Hp negative gastric cancer´Â µÎ Á¾·ù°¡ ÀÖ½À´Ï´Ù. (1) GC arising in the Hp-uninfected mucosa (familial GC, EBV-associated GC, autoimmune gastritis-associated GC, sporadic cancer with unknown cuases)¿Í (2) GC arising in the mucosa infected with Hp in the pase (spontaneous disappearance - advanced atrophy/IM, post-eradication therapy)
Hp À½¼ºÀ» Á¤ÀÇÇÏ´Â °ÍÀº °£´ÜÇÑ ÀÏÀÌ ¾Æ´Õ´Ï´Ù. Current infection »Ó¸¸ ¾Æ´Ï¶ó past infectionµµ ÀÖÀ¸¸ç ¸ðµç °Ë»ç°¡ ÀÏÁ¤ÇÑ Á¤µµÀÇ false negative¸¦ °¡Áö°í Àֱ⠶§¹®ÀÔ´Ï´Ù. ´Ù¸¥ ¸ðµç °Ë»ç¿¡¼ À½¼ºÀÌ°í ´ÜÁö CagA Ç×ü¸¸ ¾ç¼ºÀÎ °æ¿ìµµ ÀÖ½À´Ï´Ù.
Hp °¨¿°ÀÌ Çѹøµµ ¾ø¾ú´ø ȯÀÚÀÇ À§¾ÏÀº ÃÖ±Ù ¸®ºä¿¡¼´Â 1.7% Á¤µµ¿´½À´Ï´Ù (Yamamoto Y. Digest Endosc 2015). Genuine Hp - gastric cancer´Â 1% ¹Ì¸¸ÀÏ °ÍÀ¸·Î »ý°¢µË´Ï´Ù. ÀÌ ºñÀ²Àº °Ë»ç¸¦ ¾ó¸¶³ª strictÇÏ°Ô Çϴ°¡¿¡ µû¶ó ´Þ¶óÁý´Ï´Ù. ¿¹¸¦ µé¾î CagA Ç×ü °Ë»ç¸¦ ÇÏ¸é ±âÁ¸ÀÇ ELISA·Î ¹ß°ßÇÏÁö ¸øÇÏ¿´´ø °ú°Å °¨¿°ÀÇ Áõ°Å¸¦ ãÀ» ¼ö ÀÖ½À´Ï´Ù. CagA Ç×ü°¡ ´Ù¸¥ Ç×ü¿¡ ºñÇÏ¿© ¿À·¡ Áö¼ÓµÇ±â ¶§¹®ÀÔ´Ï´Ù.
FAP ȯÀÚ¿¡¼µµ °£È¤ À§ Á¾¾çÀÌ ¹ß»ýÇÕ´Ï´Ù.
Nakamura K. Endoscopy International Open 2017
Pyloric gland adenoma´Â misnomerÀÔ´Ï´Ù (Hashimoto. Histopathology 2015). ¿Ö³ÄÇϸé À̸§°ú ´Þ¸® fundic gland¿¡¼ ¹ß»ýÇϱ⠶§¹®ÀÔ´Ï´Ù. Background gastric mucosa´Â atrophicÇÑ °æ¿ì°¡ ¸¹Àºµ¥ ƯÈ÷ autoimmune atrophy¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù (Vieth M. Virchows Arch 2003).
EBV positive gastric cancer (Gastroenterology 2009;137:824-33, Fukayamo M. Pathology International 2010:60:337-50, Wu Gastroenterology 2000;118:1031-8). ³²ÀÚ¿¡ ¸¹°í lymphoepithelioma-like lesionÀÌ ÀÖ½À´Ï´Ù. ´ëºÎºÐ Hp °¨¿°ÀÌ ÀÖ½À´Ï´Ù. EBV°¡ Hp ¾øÀÌ ´Üµ¶À¸·Î À§¾ÏÀ» ÀÏÀ¸Å°´Â °æ¿ì´Â ¸Å¿ì Àû½À´Ï´Ù. EBV-related Hp negative gastric cancer is very rare (Gastroenterology 2015;129:2058-63).
Pernicous anemia°¡ autoimmune gastritis¿Í °°Àº ¸»Àº ¾Æ´Õ´Ï´Ù. Autoimmune gastritisÀÇ ÀϺδ Hp °¨¿°°ú °ü·ÃµÇ¾î ÀÖ½À´Ï´Ù. Hp°¨¿°ÀÚ¿¡¼ parietal cell¿¡ ´ëÇÑ ÀÚ°¡ Ç×ü°¡ ÈçÈ÷ ¹ß°ßµË´Ï´Ù (Helicobacter 2001;6:225-33). Hp negastive autoimmune gastritis¿¡¼ (type I carcinoid°¡ Á¾Á¾ ¹ß»ýÇÏÁö¸¸) À§¾Ï ¹ß»ýÀº rare ÇÕ´Ï´Ù (Rugge. APT 2012:35:1460). Pyloric gland adenomaÀÇ ÀϺδ autoimmune gastritis¿Í °ü·ÃÀÌ ÀÖ½À´Ï´Ù (Virchows Arch 2003;442:317-21).
Hp negastive gastric cancer¿¡¼µµ differentiated typeÀÌ undifferentiated type º¸´Ù ¸¹¾Ò½À´Ï´Ù. ƯÀÌÇÑ Á¡Àº gastric cancer wth fundic gland differentiationÀ» º¸ÀÌ´Â °æ¿ì°¡ ¸¹´Ù´Â °ÍÀÔ´Ï´Ù.
GC occurring after eradication of H. pylori´Â ±¹°¡¿¡ µû¶ó ´Ù¸¥ ¾ç»óÀ» º¸ÀÔ´Ï´Ù. ÀϺ»¿¡¼´Â ´ëºÎºÐ Á¶±âÀ§¾ÏÀ̾ú°í overseas¿¡¼´Â ÁøÇ༺ À§¾ÏÀÌ ¸¹¾Ò½À´Ï´Ù. ¾Æ¸¶µµ missed cancer¿´À» °¡´É¼ºÀÌ Å®´Ï´Ù. Á¦±ÕÄ¡·á ÈÄ ¹ß»ýÇÏ´Â À§¾ÏÀÇ À§ÇèÀÎÀÚ´Â ¿ª½Ã À§Ã༺ À§¿°ÀÔ´Ï´Ù.
Sugano ±³¼ö´ÔÀÇ ¸ÚÁø °ÀÇ´Â ¾Æ·¡¿Í °°Àº ½½¶óÀ̵å·Î ³¡³µ½À´Ï´Ù.
Hyun Gyung Kwon (°Ç±¹´ë). Alcohol drinking increases seroconversion in Hp-seronegative Korean.
264¸í Áß 27¸í¿¡¼ seroconversionÀÌ µÇ¾ú´Âµ¥ ±× Áß 6¸íÀÌ heavy alcohol drinking, 13¸íÀÌ social drinking ±×·ì¿¡ ¼ÓÇÏ¿© seroconversionÀÌ µÇÁö ¾ÊÀº group¿¡ ºñÇÏ¿© ÀǹÌÀÖ´Â Â÷ÀÌ°¡ ÀÖ¾ú½À´Ï´Ù.
ÃÖÀÏÁÖ (±¹¸³¾Ï¼¾ÅÍ). Hp treatment for metachronous gastric cancer prevention; a randomized double blind placebo-controlled trial.
5³â ½ÃÁ¡¿¡¼ ºñÄ¡·á±º¿¡¼ 12.4%, Ä¡·á±º¿¡¼ 5.5%ÀÇ metachronous gastric cancer°¡ ¹ß°ßµÇ¾ú½À´Ï´Ù (p=0.0294). HR°¡ 0.495·Î ÀǹÌÀÖ°Ô °¨¼ÒµÇ¾ú½À´Ï´Ù. Ä¡·á±º¿¡¼ À§Ã¼ºÎÀÇ À§Ã༺ À§¿°°ú È»ý¼º À§¿°Àº È£ÀüÀ» º¸¿´´Âµ¥ ÀüÁ¤ºÎ¿¡¼´Â º¯È°¡ ¾ø¾ú½À´Ï´Ù.
Tae-Geun Gweon (Incheon St. Mary's Hospital) Cost effectiveness of clarithromycin resistance test using polymerase chain reaction for the treatment of Hp
Conclusion: PCR group showed similar overall eradication rates compared with non-PCR group. Medical cost was higher in the PCR group. Usefulness of Hp-PCR should be investigated further in future studies.
Lee Sunpyo (Asan Medical Center). The efficacy of a 3D-printed training simulator for endoscopic biopsy in the stomach.
* Âü°í: EndoTODAY Simulator¸¦ ÀÌ¿ëÇÑ ³»½Ã°æ ±³À°
3. Selected poster presentation
[POS-09] Longer observation time increases the detection rate of neoplasms in EGC: a quality indicator study °¡Å縯´ëÇб³ ¹ÚÀç¸í
A higher neoplasm detection rate was found among endoscopists who had a longer mean examination time during EGD.
[ÀÌÁØÇà ÇѸ¶µð] °ÇÁø À§³»½Ã°æ¿¡¼ °Ë»ç½Ã°£ÀÌ ±æ¼ö·Ï, Á¶Á÷°Ë»ç¸¦ ¸¹ÀÌ ÇÒ¼ö·Ï Á¾¾çÀ» ¸¹ÀÌ ¹ß°ßÇÑ´Ù´Â µ¥ÀÌŸÀ̸ç, multivariate analysis¿¡¼ °Ë»ç ½Ã°£ÀÌ Áß¿äÇÑ quality indicator¿´½À´Ï´Ù. ¸Å¿ì Áß¿äÇÑ ÀÚ·á°¡ ¾Æ´Ò ¼ö ¾ø½À´Ï´Ù. ´Ù¸¸ ¿ì·Á½º·¯¿î °ÍÀº ³Ê¹« ¸¹Àº Á¶Á÷°Ë»çÀÔ´Ï´Ù. ³»½Ã°æ Á¶Á÷°Ë»ç°¡ 6.9-27.8%ÀÇ È¯ÀÚ¿¡¼ ½ÃÇàµÇ¾ú°í, Á¾¾çÀº 0.14-0.32%¿¡¼ ¹ß°ßµÇ¾ú½À´Ï´Ù. ´ë° 100°³ Á¶Á÷°Ë»ç¿¡¼ 1°³ Á¾¾çÀÌ ³ª¿Ô´Ù´Â À̾߱âÀÔ´Ï´Ù. ÀúÀÇ ÀÓ»ó °æÇèÀ¸·Î ÆÇ´ÜÇϸé Á¶Á÷°Ë»ç Áß 1%¿¡¼ Á¾¾çÀÌ ³ª¿Ô´Ù´Â °ÍÀº ³Ê¹« ³·Àº ¼öÄ¡ÀÎ °Í °°½À´Ï´Ù. °ÇÁø À§³»½Ã°æ¿¡¼ Á¶Á÷°Ë»çÀÇ threshold°¡ ³Ê¹« ³·Àº °ÍÀº ¾Æ´ÑÁö ¿ì·ÁµË´Ï´Ù. ÀÌ ºÎºÐ¿¡ ´ëÇÏ¿© Á» ´õ »ìÆ캼 ÇÊ¿ä°¡ ÀÖÀ» °Í °°½À´Ï´Ù.
*Âü°í: EndoTODAY À§³»½Ã°æ Áú°ü¸®, ÁúÁöÇ¥
4. International symposium II Áß Sugano ±³¼ö´Ô °ÀÇ - Consequence of insurance approval of eradication therapy in Japan. Kentaro Sugano (Jichi Medical University, Japan)
°ÀǸ¦ µèÁö ¸øÇßÀ¸³ª Á¦¸ñÀÌ ´«¿¡ µé¾î¿Í abstract¸¦ Àо¾Ò½À´Ï´Ù. µ¿¹æ¿¹ÀÇÁö±¹¿¡¼´Â »ó»óÇÒ ¼öµµ ¾ø´Â Ç¥ÇöÀÌ µé¾îÀÖ¾î¼ ±ô¦ ³î¶ú½À´Ï´Ù (ºÓÀº »ö °Á¶).
Hp infection as a major risk factor of a number of major gastric diseases such as ulcer and cancer is well established. Yet, many guidelines except for the Japanese guidelines have not recommended the eradication therapy for Hp. However, peptic ulcer and cancer associated with Hp will perpetuate in infected subjects unless the infection is eradicated. Since the eradication therapy requires substantial cost, it is important to facilitate eradication therapy by subsidizing the cost by public insurance. In Japan, the government expanded insurance coverage to include Hp infection in 2014 after a several years of petitions by the academic societies. This policy was approved by the Kyoto Consensus, and now incorporated into the Maastricht V/Florence consensus. Since then, dramatic surge of the number of eradication therapy took place and continued since then, which we estimated to be about 1.4 million based on the nation-wide market sales of bothe 13C-urea breath test and packaged regimen for eradication therapy. This insurance policy includes either screening of serious organic diseases such as peptic ulcer or cancer before receiving eradication therapy to ascertain that these conditions would not be left untreated, implying primary and secondary prevention can be done. If we assume that 70% of elderly population infected with Hp disappears due to death, about 2.4 millon infected persons are disappearing from Japan.For eradication therapy, despite of increasing antibiotic resistance rate, we can maintain high eradication success due to potassium-competitive acid blocker (P-CAB)-based triple therapy, now the first choice for eradication therapy in Japan, achieving more than 90% of eradication success in a week. Based on these assumptions, we predict that the infection rate in Japan will decreased to about 10%, current levels of the Western Europe and USA, and Hp will almost be eliminated from the country by 2050. Such a sharp decline of Hp infection would dramatically decrease the prevalence and mortality of gastric cancer. Indeed, recent statistics clearly showed that the numbers of gastric cancer death are declining for 4 consecutive years, depite of the stable trend predicted by national cancer institue. If this trend continues, the mortality from gastric cancer in Japan would be greately reduced in a decade or two. Although we need to carefully watch the untoward effects of eradication therapy, implementation of eradication therapy for Hp infection at the nation level would accelerate to eliminate the infection and hence a large number of people's lives can be saved from gastric cancer death.
1) ´ëÇÑ»óºÎÀ§Àå°üÇ︮ÄÚ¹ÚÅÍÇÐȸ ÇмúÇà»ç Áö»óÁß°è
© ÀÏ¿ø³»½Ã°æ±³½Ç ¹Ù¸¥³»½Ã°æ¿¬±¸¼Ò ÀÌÁØÇà. EndoTODAY Endoscopy Learning Center. Lee Jun Haeng.